May 1st 2024
COVID-19 and worsening myasthenia gravis (MG) were the most common treatment-emergent adverse events, the study found.
Older Age, Male Sex Identified as Potential Risk Factors for MG Following COVID-19 Vaccination
October 18th 2023A new analysis has determined potential risk factors for developing myasthenia gravis following COVID-19 vaccination, with symptoms likely to appear within 2 weeks of receipt of a COVID-19 vaccine.
Read More
gMG Imposes an Enormous Economic Burden on Patients
October 10th 2023Qualitative interviews were conducted and a web-based quantitative survey was administered to have a clearer understanding of the economic impact of social determinants of health on patients living with generalized myasthenia gravis (gMG).
Read More
Subanalysis of ADAPT Reveals Consistent Efficacy With Efgartigimod Among All Genders
September 29th 2023Patients with generalized myasthenia gravis treated with efgartigimod consistently exceeded treatment compared with placebo regardless of gender in age, disease duration, body mass index, and thymectomy.
Read More
ICI Treatment Necessitates Close Monitoring of Potential Myasthenia Gravis
September 25th 2023Overactivation of the immune system is a potential serious adverse event (AE) following immune checkpoint inhibition (ICI) treatment for any of several cancers in the first and second line; among these AEs is myasthenia gravis.
Read More
Zilucoplan Demonstrates Consistent Efficacy in Phase 3 RAISE Study of Generalized Myasthenia Gravis
August 5th 2023Nearly half of patients treated with zilucoplan were considered responders on Myasthenia Gravis Activities of Daily Living (MG-ADL) at the first week, suggesting a rapid onset of efficacy.
Read More
Case Investigated of Patient With Possible COVID-19–Induced Myasthenia Gravis
August 2nd 2023Investigators conducted a case study of a patient who presented with COVID-19–induced seronegative myasthenia gravis, seeking more information on neurological manifestations of the respiratory disease.
Read More